Abstract: The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.

Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.

Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.

Abstract: Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator

Abstract: The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.

Abstract: The invention relates to genetic variants useful for evaluating creatine kinase levels in a subject and determining an Nupper limit of normal (ULN) CK level for a subject. ULN CK level is used in determining the pathological significance of measures of blood or plasma CK obtained from the subject. The methods and compositions of the invention are useful for providing a genetic-C ally determined or individualized ULN CK level, for diagnosing statin-induced myopathy and for providing statin therapy.

Abstract: The present invention features pharmaceutical compositions and methods of using pharmaceutical compositions for treating left ventricular diastolic dysfunction. In particular, the pharmaceutical compositions include an apolipoprotein complex comprising a lipid fraction and a protein fraction.

Abstract: The present invention features pharmaceutical compositions and methods of using pharmaceutical compositions for treating left ventricular diastolic dysfunction. In particular, the pharmaceutical compositions include an apolipoprotein complex comprising a lipid fraction and a protein fraction.

Abstract: The present invention features pharmaceutical compositions and methods of using the pharmaceutical compositions for treating left ventricular diastolic dysfunction. In particular, the pharmaceutical compositions include an apolipoprotein complex comprising a lipid fraction and a protein fraction.

Abstract: A method for treating valvular stenosis. The method involves the administration of a therapeutically effective amount of a reverse lipid (in particular cholesterol) transport agonist to a mammal. Most preferred is an Apolipoprotein A-1 mimetic peptide/phospholipid complex, the peptide of which is defined by the amino acid sequence of SEQ ID NO 1.

Abstract: The present invention features pharmaceutical compositions and methods of using the pharmaceutical compositions for treating left ventricular diastolic dysfunction. In particular, the pharmaceutical compositions include an apolipoprotein complex comprising a lipid fraction and a protein fraction.

Abstract: Use of ivabradine, or 3-{3-[{[(7S)-3,4-dimethoxybicyclo [4.2.0]octa-1,3,5-trien-7-yl]-methyl }-(methyl)-amino]-propyl}-7,8-dimethoxy-1,3,4,5 -tetrahydro-2H-3-benzazepin-2-one, its addition salts with a pharmaceutically acceptable acid and their hydrates, for obtaining a medicament intended for the treatment of endothelial dysfunction.

Abstract: A method for characterizing oxidative stress. The method includes dosing a ratio of HNE-to-DHN-protein in blood; comparing the ratio of HNE-to-DHN-protein in blood to a predetermined interval of ratio values associated with a predetermined level of oxidative stress; and classifying the oxidative stress as having reached the predetermined level if the ratio of HNE-to-DHN-protein in blood is within the predetermined interval of ratio values.

Abstract: The present invention relates to methods for detecting a oxidative stress in a biological sample, methods of determining a cumulative record of oxidative injury, and methods of diagnosing diseases of aging, such as cardiovascular diseases, based on the presence or absence of a biomarker or a component thereof. The present invention also relates to a kit for detecting oxidative stress in a biological sample comprising a stabilizing reactant and an antibody. In some embodiments of the invention, the biomarker of oxidative stress is selected from an aldehyde-protein adduct and an aldehyde metabolite-protein adduct, and the proposed method further comprises measuring separately for the same protein biomarkers of oxydative stress formed with different amino acids of the protein.

Abstract: The present invention provides methods for preventing or treating a valvular stenosis or a valvular calcification in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a peptide/phospholipid complex, wherein the peptide of the complex is an Apolipoprotein A-1 mimetic peptide. In one embodiment the Apolipoprotein A-1 mimetic peptide has the sequence set forth in SEQ ID NO: 1. In another embodiment the phospholipid of the complex is egg sphingomyelin and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine.

Abstract: The present invention relates to methods for detecting a oxidative stress in a biological sample, methods of determining a cumulative record of oxidative injury, and methods of diagnosing diseases of aging, such as cardiovascular diseases, based on the presence or absence of a biomarker or a component thereof. The present invention also relates to a kit for detecting oxidative stress in a biological sample comprising a stabilizing reactant and an antibody. In some embodiments of the invention, the biomarker of oxidative stress is selected from an aldehyde-protein adduct and an aldehyde metabolite-protein adduct, and the proposed method further comprises measuring separately for the same protein biomarkers of oxydative stress formed with different amino acids of the protein.

Abstract: A method for treating valvular stenosis The method involves the administration of a therapeutically effective amount of a reverse lipid (in particular cholesterol) transport agonist to a mammal Most preferred is an Apolipoprotein A-1 mimetic peptide/phospholipid complex, the peptide of which is defined by the amino acid sequence of SEQ ID NO 1.

Abstract: Use of ivabradine, or 3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-methyl}-(methyl)-amino]-propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-one, its addition salts with a pharmaceutically acceptable acid and their hydrates, for obtaining a medicament intended for the treatment of endothelial dysfunction.

Abstract: The present invention relates to the effect of angiotensin-converting enzyme (ACE) inhibitors on the prevention of diabetes in a subject with left ventricular dysfunction. A retrospective study was conducted to assess the effect of the ACE inhibitor enalapril on the incidence of diabetes in a group of patients from the Montreal Heart Institute enrolled in the Studies of Left Ventricular Dysfunction (SOLVD). Clinical charts were evaluated for fasting plasma glucose (FPG) levels by blinded reviewers. A diagnosis of diabetes was made when a FPG≧126 mg/dL (7 mmol/L) was found at 2 visits (follow-up, 2.9±1.0 years). Of the 291 non-diabetic patients enrolled in the SOLVD study, 153 of these were on enalapril and 138 were on placebo. Baseline characteristics were similar in the 2 groups. Forty patients developed diabetes during follow-up, 9 (5.9%) in the enalapril group and 31(22.4%) in the placebo group (P<0.0001).

Abstract: Atrial fibrillation (AF) is frequently encountered in patients with heart failure (HF) and is also a predictor of morbidity and mortality in this population. Recent experimental studies have shown electrical and structural atrial remodeling with increased fibrosis in HF animals, and have suggested a preventive effect of angiotensin converting enzyme inhibitors (ACEi) on the development of AF. To verify the hypothesis that ACEi prevent the development of AF in patients with HF, a retrospective analysis of the patients from the Montreal Heart Institute (MHI) included in the Studies Of Left Ventricular Dysfunction (SOLVD) was conducted. The results of this retroactive analysis indicate that treatment with the ACE inhibitor, such as enalapril, can markedly reduce the risk of developing atrial fibrillation in patients with left ventricular dysfunction.